Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
Cancer Res Treat. 2005 Apr;37(2):92-7. doi: 10.4143/crt.2005.37.2.92. Epub 2005 Apr 30.
There has been no definitive randomized study to identify the optimal therapeutic regimen for treating squamous cell carcinoma of tonsil. The purpose of this study was to retrospectively evaluate the treatment outcome according to various combinations of surgery, radiation therapy and chemotherapy.
Fifty-six patients with tonsillar carcinoma, who were treated at Seoul National University Hospital from March 1985 to August 2001, were the subjects of this study. Twenty-one patients received surgery followed by radiation therapy (SRT), 16 patients underwent radiation therapy alone (RT), and 19 patients received neoadjuvant chemotherapy and radiation therapy (CRT). The median radiation dose was 66.6 Gy for the SRT group and 70.2 Gy for the RT and CRT groups. Surgery comprised extended tonsillectomy and modified radical neck dissection of the involved neck. Cisplatin and 5-fluorouracil were used every three weeks for 3 cycles in the SRT group. The median follow-up was 73.2 months.
The distribution of T-stage was 4 cases of T1, 14 cases of T2, 1 case of T3 and 2 cases of T4 staging in the SRT group, 2 cases of T1, 6 cases of T2, 5 cases of T3 and 3 cases of T4 staging in the RT group and 0 cases of T1, 7 cases of T2, 9 cases of T3 and 3 cases of T4 staging in the CRT group. The distribution of N-stage was 5 cases of N0, 2 cases of N1, 13 cases of N2 and 1 case of N3 staging in the SRT group, 6 cases of N0, 5 cases of N1, 5 cases of N2 and 0 cases of N3 staging in the RT group, and 2 cases of N0, and 7 cases of N1, 9 cases of N2 and 1 case of N3 staging in the CRT group. The five-year overall survival rate (OSR) for all patients was 78%. The five-year OSR was 80% for the SRT group, 71% for the RT group, and 80% for the CRT group (p=ns). The five-year disease-free survival rate was 93% for the CRT group and 71% for the RT group (p=0.017). Four patients developed local failure and one patient failed at a regional site in the RT group, and one patient failed at a primary site in the CRT group. The five-year DFS was 84% for patients who had undergone neck dissection and 76% for patients who had not undergone neck dissection (p=ns). Treatment-related complications of grade 3 or 4 occurred in 15 patients, and the incidence of complication was not different between each of the treatment methods.
Although the patients with more advanced T stage were included in the RT and CRT groups, the OSR was not statistically different according to the treatment methods. In the radical radiation therapy group, the addition of neoadjuvant chemotherapy showed an improvement in the disease-free survival. Because of the retrospective nature of our study and the small number of patients, this study cannot draw any definite conclusions, but it suggests that radiation therapy with chemotherapy can be a good alternative option for squamous cell carcinoma of tonsil. Controlled randomized study is necessary to confirm this hypothesis.
目前尚无明确的随机研究来确定治疗扁桃体鳞状细胞癌的最佳治疗方案。本研究的目的是回顾性评估根据手术、放疗和化疗的不同组合的治疗结果。
56 例扁桃体癌患者于 1985 年 3 月至 2001 年 8 月在首尔国立大学医院接受治疗,为本研究的对象。21 例患者接受手术联合放疗(SRT),16 例患者接受单纯放疗(RT),19 例患者接受新辅助化疗联合放疗(CRT)。SRT 组的中位放疗剂量为 66.6Gy,RT 和 CRT 组为 70.2Gy。手术包括扩大扁桃体切除术和受累颈部改良根治性颈淋巴结清扫术。SRT 组每 3 周使用顺铂和 5-氟尿嘧啶 3 个周期。中位随访时间为 73.2 个月。
SRT 组 T 分期为 4 例 T1、14 例 T2、1 例 T3 和 2 例 T4,RT 组为 2 例 T1、6 例 T2、5 例 T3 和 3 例 T4,CRT 组为 0 例 T1、7 例 T2、9 例 T3 和 3 例 T4。N 分期为 SRT 组 5 例 N0、2 例 N1、13 例 N2 和 1 例 N3,RT 组 6 例 N0、5 例 N1、5 例 N2 和 0 例 N3,CRT 组 2 例 N0 和 7 例 N1、9 例 N2 和 1 例 N3。所有患者的 5 年总生存率(OSR)为 78%。SRT 组的 5 年 OSR 为 80%,RT 组为 71%,CRT 组为 80%(p=ns)。5 年无病生存率为 CRT 组 93%,RT 组 71%(p=0.017)。RT 组 4 例局部复发,1 例区域复发,CRT 组 1 例原发灶复发。行颈部清扫术患者的 5 年无病生存率为 84%,未行颈部清扫术患者为 76%(p=ns)。15 例患者发生 3 级或 4 级治疗相关并发症,各治疗方法的并发症发生率无差异。
尽管 RT 和 CRT 组纳入了更多晚期 T 期患者,但根据治疗方法,OSR 无统计学差异。在根治性放疗组中,新辅助化疗的加入改善了无病生存率。由于本研究为回顾性研究且患者数量较少,因此无法得出任何明确结论,但提示化疗联合放疗可作为扁桃体鳞状细胞癌的一种较好选择。需要进行对照随机研究来证实这一假设。